CLINUVEL Pharmaceuticals secures Canadian marketing approval for SCENESSE®, expanding access to the only approved systemic photoprotective treatment for erythropoietic protoporphyria (EPP).
- Health Canada issues Notice of Compliance for SCENESSE® in EPP
- SCENESSE® is the only globally approved systemic photoprotective drug for EPP
- Canadian Specialty Centers established for patient treatment
- Over 21,000 SCENESSE® doses administered worldwide with long-term safety
- EPP affects approximately 1 in 140,000 Canadians
Canadian Approval Opens New Market for SCENESSE®
CLINUVEL Pharmaceuticals (ASX:CUV) has finally secured Health Canada’s Notice of Compliance (NOC) for its flagship drug SCENESSE® (afamelanotide), allowing commercial marketing for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). This milestone formally authorises the drug’s sale in Canada, a market where CLINUVEL has already laid groundwork through Specialty Centers treating patients under special access programs.
SCENESSE®’s Unique Position in EPP Treatment
SCENESSE® stands alone as the only systemic photoprotective therapy approved worldwide for EPP, a rare metabolic disorder that causes severe, debilitating skin reactions triggered by sunlight. The drug’s approval in Canada follows earlier regulatory green lights in Europe (2014), the United States (2019), and Australia (2020), cementing its global footprint in this niche but critical therapeutic area.
Containing 16mg of afamelanotide, a synthetic analogue of a natural hormone, SCENESSE® stimulates melanin production to shield skin from harmful light penetration while also providing antioxidant benefits. With over 21,000 doses administered globally and some patients on continuous treatment for up to 20 years, the drug’s long-term safety profile is well established.
Building Infrastructure for Canadian Patients
CLINUVEL has proactively developed a network of five accredited Specialty Centers across Canada, enabling physicians trained in SCENESSE® administration to provide treatment in outpatient settings. These centers have already treated EPP patients under special access arrangements, smoothing the transition to full commercial availability.
Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer, acknowledged the protracted regulatory process but emphasised the robust data underpinning the approval, including extensive postmarketing experience. He highlighted the drug’s consistent safety record as a key differentiator from competitors still in development.
EPP’s Impact and Treatment Challenges
EPP is estimated to affect between 5,000 and 10,000 people globally, with roughly one in every 140,000 Canadians diagnosed. The disorder triggers painful phototoxic reactions after even brief exposure to visible light, severely restricting patients’ quality of life. Until SCENESSE®, treatment options were limited and largely supportive rather than preventative.
This approval not only expands patient access in Canada but also reinforces CLINUVEL’s position as a leader in photomedicine and rare disease therapies. The company continues to advance its pipeline and regulatory engagements, including recent moves to upgrade its U.S. ADR listing to Nasdaq and progress in vitiligo clinical trials.
Bottom Line?
Canadian approval for SCENESSE® marks a strategic expansion for CLINUVEL, but the pace of market uptake and reimbursement dynamics will shape near-term commercial impact.
Questions in the middle?
- How quickly will Canadian payers and healthcare systems adopt SCENESSE® following approval?
- What patient enrolment rates can Canadian Specialty Centers sustain post-commercial launch?
- Will CLINUVEL leverage this approval to accelerate regulatory progress in other rare disorder indications?